Cutler Group’s Pliant Therapeutics PLRX Stock Holding History

Cutler Group’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,400	Closed	-$3K	–	4043
2023 Q1	$3K	Buy	+2,400	New	+$68.3K	﹤0.01%	3002

Other funds holding PLRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Cutler Group's PLRX Position: Q1 2024 in Review

Cutler Group sold out of Pliant Therapeutics (PLRX) in Q1 2024, closing a stake of 900 shares — an estimated $16K sold.

Cutler Group first reported a position in PLRX in Q2 2022 and held it in 7 quarters. The position peaked at $85K in Q1 2023. 135 funds tracked by Wall St. Rank hold PLRX as of Q1 2024.

Cutler Group reported no remaining Pliant Therapeutics position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 900 Pliant Therapeutics shares in Q1 2024, an estimated $16K.
Cutler Group first reported a position in Pliant Therapeutics in Q2 2022 and held it in 7 quarters.
Cutler Group's Pliant Therapeutics position peaked at $85K in Q1 2023.
135 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.